Patient and graft characteristics
| Characteristic . | n (%) . |
|---|---|
| No. of patients | 23 |
| Phase 1a | 13 (57) |
| Phase 1b | 10 (43) |
| Median age, y (range) | 59 (26-72) |
| Female sex | 11 (48) |
| Donor-patient sex matching | |
| M-M | 6 (26) |
| M-F | 6 (26) |
| F-M | 3 (13) |
| F-F | 8 (35) |
| HLA typing | |
| Mismatched HLA-A only | 7 (30) |
| Mismatched HLA-B only | 7 (30) |
| Mismatched HLA-B and C | 3 (13) |
| Mismatched HLA-C only | 5 (21) |
| Mismatched HLA-DRB1 only | 1 (4) |
| 1 antigen mismatched | 12 (52) |
| 2 antigen mismatched | 2 (9) |
| 1 allele mismatched | 8 (35) |
| Both 1 antigen and 1 allele mismatched | 1 (4) |
| Disease status at transplantation | |
| First CR/chronic phase | 10 (43) |
| Second or later CR/chronic phase | 1 (4) |
| PR or accelerated phase | 8 (36) |
| Relapse or blastic phase | 1 (4) |
| Induction failure | 1 (4) |
| Untreated | 2 (9) |
| Disease | |
| AML | 9 (39) |
| NHL | 5 (22) |
| CLL/SLL/PLL | 3 (13) |
| HL | 3 (13) |
| MDS | 1 (4) |
| MPD* | 2 (9) |
| High risk† | 14 (61) |
| Prior transplantation | 4 (17) |
| Characteristic . | n (%) . |
|---|---|
| No. of patients | 23 |
| Phase 1a | 13 (57) |
| Phase 1b | 10 (43) |
| Median age, y (range) | 59 (26-72) |
| Female sex | 11 (48) |
| Donor-patient sex matching | |
| M-M | 6 (26) |
| M-F | 6 (26) |
| F-M | 3 (13) |
| F-F | 8 (35) |
| HLA typing | |
| Mismatched HLA-A only | 7 (30) |
| Mismatched HLA-B only | 7 (30) |
| Mismatched HLA-B and C | 3 (13) |
| Mismatched HLA-C only | 5 (21) |
| Mismatched HLA-DRB1 only | 1 (4) |
| 1 antigen mismatched | 12 (52) |
| 2 antigen mismatched | 2 (9) |
| 1 allele mismatched | 8 (35) |
| Both 1 antigen and 1 allele mismatched | 1 (4) |
| Disease status at transplantation | |
| First CR/chronic phase | 10 (43) |
| Second or later CR/chronic phase | 1 (4) |
| PR or accelerated phase | 8 (36) |
| Relapse or blastic phase | 1 (4) |
| Induction failure | 1 (4) |
| Untreated | 2 (9) |
| Disease | |
| AML | 9 (39) |
| NHL | 5 (22) |
| CLL/SLL/PLL | 3 (13) |
| HL | 3 (13) |
| MDS | 1 (4) |
| MPD* | 2 (9) |
| High risk† | 14 (61) |
| Prior transplantation | 4 (17) |
HLA indicates human leukocyte antigen; CR, complete remission; PR, partial response; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; PLL, prolymphocytic leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; and MPD, myeloproliferative disease.
The protocol was subsequently amended to exclude MPD patients.
Patients other than those with AML or ALL in CR1, or CML in chronic phase, or patients with AA, or MDS with RA or RARS.